U.S. market Closed. Opens in 4 hours 37 minutes

MRK | Merck & Co., Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 96.66 - 98.84
52 Week Range 94.48 - 134.63
Beta 0.24
Implied Volatility 24.10%
IV Rank 52.01%
Day's Volume 7,722,825
Average Volume 9,632,073
Shares Outstanding 2,529,640,000
Market Cap 246,488,121,600
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 1978-01-13
Valuation
Profitability
Growth
Health
P/E Ratio 20.38
Forward P/E Ratio 34.78
EPS 4.78
1YR Price Target 125.00
Dividend Yield 3.19%
Dividend Per Share 2.20
Dividend ExDate 2023-09-14
Dividend PayDate 2023-10-06
Employees 70,000
Country USA
Website MRK
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
MRK's peers: ABBV, AMGN, AMRN, AZN, BIIB, BMY, GILD, GRFS, GSK, JNJ, LLY, PFE, NVS, OGN, SNY, SCLX
*Chart delayed
Analyzing fundamentals for MRK we got that it has strong fundamentals where Valuation is considered to be significantly undervalued, Profitability is very wealthy, Growth is very good and Health is strong. For more detailed analysis please see MRK Fundamentals page.

Watching at MRK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MRK Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙